Study #2024-0330
A phase I/II combination study of NMS-03305293 and Temozolomide in adult patients with recurrent Glioblastoma
MD Anderson Study Status
Enrolling
Treatment Agent
NMS-03305293, Temozolomide
Description
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma, Diffuse Glioma
Study phase:
Physician name:
Nazanin Majd
Department:
Neuro-Oncology
For general questions about clinical trials:
1-844-936-2191
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.